Pharmaceuticals
BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody
WUXI, China, Aug. 7, 2023 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC3448 (CD3/EGFR Bispecific antibody, BsAb). As a result, BioCity Biopharma will...
2023-08-07 16:14
1371
The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC
HONG KONG, Aug. 7, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that eClinical Medicine(IF:15.1), a sub-j...
2023-08-07 12:29
2075
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL
ROCKVILLE, Md. and SUZHOU, China, Aug. 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that lisaftoclax (APG-2575), a novel Bcl-2 inhibitor...
2023-08-07 09:43
1824
JinMed's Nanobathing Products Receive Multiple Patent Certifications and Sign Directed Procurement Agreement with Shanghai Zhongjin HongKang Medical Technology
CHANGZHOU, China, Aug. 3, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("the Company" or "JinMed") (NASDAQ: ZJYL) which is the world's leading provider of rehabilitation equipment. Currently, the Company's nanobathing products have been granted an invention patent and four utility model pa...
2023-08-03 17:13
1142
ESMO 2023 | Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress
SUZHOU, China, and ROCKVILLE, Md., Aug. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it is going to release results from two clinic...
2023-08-03 11:43
1328
SK Biopharmaceuticals Assembles 'Board of Prominent Experts' to Boost Growth, Innovation
Renowned oncologist Yung-Jue Bang, M.D., Ph.D., chairs the distinguished 5-member Scientific Advisory Board to further advance SK Biopharmaceuticals as a global big biotech SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation o...
2023-08-03 07:30
1404
Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting
SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing novel immunotherapies targeted for advanced gastrointestinal cancers, presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough c...
2023-08-03 07:00
1297
Peijia Medical Announces First Chinese Patient Implanted with TaurusTrio™ Transcatheter Aortic Valve Replacement System
SUZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, announced onJuly 31, 2023 that the first Chinese patient of the multi-center ...
2023-08-01 20:00
2307
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2023-08-01 17:08
1150
Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC
* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...
2023-08-01 00:00
1411
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...
2023-07-31 20:30
2206
111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...
2023-07-31 17:59
1652
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...
2023-07-31 17:05
1533
U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
2023-07-31 13:20
1681
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:27
2756
Wuan Ankang Hospital's Innovative Tumor Treatment Attracts Many Patients
HANDAN, China, July 28, 2023 /PRNewswire/ -- In Handan City, Hebei Province, China, the Wu'an Ankang Hospital has 35-year of experience with tumor treatment. It has now become a second-class general hospital. The reason it attracts many patients from bothChina and abroad is that they practice hol...
2023-07-28 14:35
1238
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...
2023-07-27 19:00
1958
AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine
- AIM Is First Japanese Company to Establish Joint Research Agreement in Field of Endoscopic AI - TOKYO, July 27, 2023 /PRNewswire/ -- AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement ...
2023-07-27 14:00
1238
Samsung Biologics Reports Second Quarter 2023 Financial Results
* Recorded Q2'23 consolidated revenue of KRW 866.2 billion * Recorded Q2'23 consolidated operating profit of KRW 253.4 billion * Achieved record-high semi-annual revenue exceeding KRW 1,587.1 billion * Strong growth sustained with successful contract wins and full completion of Plant 4 set ...
2023-07-26 15:23
1956
Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
SHANGHAI, July 25, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Hu...
2023-07-26 00:00
1867
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7722
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7116